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Regulation challenge of tissue engineering 
and regenerative medicine in China
Introduction
For patients with extensive burns, the restoration of  skin 
barrier function could make the difference between life and 
death, and it was this acute need that drove the initiation 
of  tissue engineering in the 1980s.[1] With the reliable 
keratinocyte culture technique, the epithelial sheets [known 
as cultured epithelial autografts (CEA)] produced from a 
small skin sample have been used to handle burn wounds.[2] 
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Although the split-thickness skin autografts are the “gold 
standard” for burn wound closure, it is limited by massive 
tissue destruction and/or unsuited donor sites (e.g. hands 
and face). A number of  approaches with cultured skin cells 
have been developed to restart the wound healing of  burns 
and chronic wounds. The allogeneic neonatal fibroblasts 
and keratinocytes are designed to be delivered in a fibrin 
spray, and this has shown preliminarily an excellent result 
in the clinical trial of  chronic venous leg ulcer treatment.[3] 
DERMAGRAFT®, composed of  fibroblasts, extracellular 
matrix, and a bioabsorbable polyglactin mesh scaffold, has 
been approved as a dermal substitute used for the treatment 
of  full-thickness diabetic foot ulcer.[4] These products and 
techniques are so different from each other, as they might be 
based on either the use of acellular matrices, cultured cells, or 
a combination of  both. But essentially, they can be thought 
of  as sprouting from tissue engineering and regenerative 
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medicine, which aim at the repair and regeneration of  the 
structure and function of  damaged tissue and organ.
Besides the skin, the researches in tissue engineering and 
regenerative medicine are involved with almost every kind of  
human tissue and organ. There are more and more evidences 
showing that the related research results might be promising 
in the clinic as an alternative to traditional clinic treatment. 
But on the other side, the medical techniques and medical 
products derived from tissue engineering and regenerative 
medicine can be very complex, which are different from 
ordinary medicinal products or medical devices. It is unlikely 
that all aspects of  tissue engineering and regenerative 
medicine can be encompassed by current legislation, for 
example, in relation to medicinal products, or medical 
devices, or clinical trials.[5] New regulatory framework 
should be developed to oversee the introduction of  these 
advanced medical products and techniques into clinic.
Concepts of tissue engineering and 
regenerative medicine
To establish the regulatory framework, the first step might be 
the development of  the definitions of  tissue engineering and 
regenerative medicine, which define the boundaries of  the 
area that will be regulated in this way. In the fourth annual 
National Institutes of  Health Bioengineering Consortium 
(BECON) Symposium held in 2001, the regenerative 
medicine was equally referred to as reparative medicine 
or tissue engineering, for which the definition presented 
was that the regeneration and remodeling of  tissue in vivo 
for the purpose of  repairing, replacing, maintaining, or 
enhancing organ function, and the engineering and growing 
of functional tissue substitutes in vitro for implantation in vivo 
as a biological substitute for damaged or diseased tissues and 
organs.[6] In fact, the term of tissue engineering was proposed 
early than that of  regenerative medicine. In this area, 
cells are typically combined with matrices to achieve new 
tissue formation.[7] With the new field of  stem cell biology 
emerging, it is found that the stem cell holds great promise 
in its potential for therapy using tissue engineering strategies. 
Thus, the term regenerative medicine is recently more referred 
to, which aptly describes the intersection of  stem cell science 
with tissue engineering.[8] It involves typically the systemic 
delivery of  stem cells in the hope of  reversing degenerative 
disease or stimulating repair post injury.[9]
Furthermore, the term regenerative medicine combines 
the elements of  tissue engineering and stem cell science 
to encompass the broad range of  scientific disciplines 
that are necessary to further the field.[10] The approaches 
under development have evolved from the earlier focus on 
replacement to the recent inclusion of repair and regeneration. 
Replacement involves the growing or fabricating of  tissues 
and organs outside the body and then implanting them. 
Repair is the biological effect at the cell and molecular level, 
including the repair of  DNA. Finally, regeneration is to 
literally grow in vivo a new tissue or organ.[11] It might also 
be noted that whether one’s strategy is replacement, repair, 
or regeneration, the approaches one uses can involve cells 
alone, cells seeded in a scaffold, or even a scaffold alone.[11] 
But the formation of  tissue and organ is achieved by cells, 
whether the cells are intentionally introduced in vitro or 
mobilized in vivo. Cells sense signals from soluble molecules, 
from the substrate/matrix to which the cells are adherent, 
and from the mechanical or physical forces acting on them. 
So, it is usually thought that cells should be the core element 
of  medical products and techniques derived from tissue 
engineering and regenerative medicine.
Regulation mode in clinic application: 
Medical technique or medical product
For the introduction of  tissue engineering and regenerative 
medicine into clinical practice, specific regulatory 
framework is required to be designed. First of  all, it 
should be considered that when tissue engineering and 
regenerative medicine are applied in clinic, they ought to 
be adopted as medical techniques or as more regulated 
medical products, which represent very different regulatory 
requirements.
In the USA, if  the cells are minimally manipulated and 
homologously used only, are not combined with a drug 
or device, and are not for metabolic use when from an 
unrelated donor [Table 1], according to the Food and 
Drug Administration (FDA), the usage of  cells can 
be carried out as a clinic technique in a well-equipped 
hospital without FDA approval,[12,13] in which only 
control of  communicable diseases is required in the 
procedure involving cells. For instance, autologous bone 
marrow – derived cells can be harvested from peripheral 
blood following stimulation with appropriate growth 
factors, definite cell populations are isolated by specific 
surface markers, and the concentrated cell preparation 
can be re-infused in the systemic circulation or in the 
affected organ.
But if  the manipulation and usage of  cells are beyond 
the above criteria, for example, the culture, expansion, 
and/or differentiation of  the cells, or cells combined with 
biomaterial scaffold, these processes are more elaborated 
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and require more complex and expensive facilities, and 
more risks should be taken care of. When tissue engineering 
and regenerative medicine are translated into clinical 
application in such matters, there should be manufacture 
quality control and they should be regulated by the FDA 
as medical products.
In the European Union (EU), similar strategy is adopted 
to determine the regulation mode of  tissue engineering 
and regenerative medicine in clinic. If  cells are only 
subjected to separation, concentration, purification, 
filtering, cryopreservation, or vitrification, and have the 
same function and are not combined with medical devices, 
their usages for the intended regeneration, repair, or 
replacement of  tissue and organ might be treated as medical 
techniques [Table 1]. Otherwise, they should be presented 
as medicinal products which are regulated for the marketing 
authorization at the European community level.[14]
In Japan, if  the use of stem cell is aimed at the regeneration 
of organs or tissues lost or damaged due to injury or disease, 
it is permitted to carry out human stem cell clinical research, 
even though the processing of cells is beyond the minimal 
manipulation, such as artificially induced proliferation, drug 
treatments intended to activate cells or elicit other effects, 
modification of  biological properties, combination with 
non-cellular components, etc.[15] This is deemed a pragmatic 
regulatory strategy since there is no proper “regulatory 
approval pathway” for the commercialization as medical 
products, for instance, some important rules have been lacking 
for preclinical studies and clinical assessment.[16] This has 
hampered the development of application in clinic as medical 
products of tissue engineering and regenerative medicine.
In China, there seem to have two parallel regulatory regimes 
that can both be applied to the transformation to the clinic 
of  tissue engineering and regenerative medicine. They are 
not mutually exclusive regulations. Medical technique 
or medical product, each of  them can be the choice, no 
matter whether the cells are minimally or substantially 
manipulated.[17,18] The current regulatory situation might 
reflect the present status of  research and development of  
tissue engineering and regenerative medicine in China, 
which are mainly in the professional medical institutions 
where the clinicians try to carry out some tissue engineering 
and regenerative medicine based treatments. But on the 
other side, it also reflects, to some degree, the predicament 
in the way of  developing medical products.
The above information represents, to some degree, 
the current regulatory situation of  tissue engineering 
and regenerative medicine [Table 1]. It is obvious that 
various kinds of  framework are designed by regulators. 
Just based on the mentioned cell-related criteria, the 
demarcation line is made clear by regulators of  the 
USA and EU to determine which regulatory mode is 
more desirable between medical technique and medical 
product. This regulatory scheme represents an ambitious 
attempt to set up a coherent and flexible framework for 
tissue engineering and regenerative medicine. In most 
researches, the cells might be subjected to substantial 
manipulation, or nonhomologous use, or combination 
with drugs or medical devices, or have systemic function/
metabolic function. In such circumstances, the risks such 
as those related to transmission of  communicable disease, 
control of  processing, and clinical safety and effectiveness 
are significant, in which the desirability of  regulation 
mode of  medical technique is challenged in nature. The 
establishment of  medical product mode should be the core 
of  regulatory framework for the introduction of  tissue 
engineering and regenerative medicine into clinic.
Current regulation as medical product in 
the USA and EU
When medical products derived from tissue engineering and 
regenerative medicine are applied in clinic, these products 
Table 1: Current status of regulation of cell-based tissue engineering and regenerative medicine
Country/region Current status
USA If it is intended to be used as medical technique in clinic, the following conditions must be fulfilled: Cells are (1) minimally manipulated, 
(2) homologously used, (3) not combined with a drug or device, and (4) have no systemic effect and do not depend upon the metabolic 
activity of living cells for the primary function (except for autologous use or allogeneic use in a first-degree or second-degree blood 
relative). Otherwise, it will be regulated as a medical product with premarket approval requirement
EU The following conditions need to be fulfilled: Cells (1) are not subjected to substantial manipulation, (2) have the same function, and (3) are 
not combined with medical devices, or if cells are prepared and used as a custom-made product for an individual patient in a hospital, their 
usage might be treated as medical technique. Otherwise, they should be presented as a medicinal product
Japan It is permitted to carry out human stem cell clinical research, even though stem cells are substantially manipulated or combined with 
non-cellular components
China There have not been any criteria related to the manipulation and usage of cells, which can be used to determine whether the medical 
technique mode or the medical product mode is desired
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are intended to have the potential of  repair, replacement, 
or regeneration of  damaged tissues and organs. These 
are generally considered as the typical characteristics that 
might be used to distinguish these medical products from 
the others, since these therapeutic effects are dependent on 
the biological function of  cells, which are different from 
the effects produced by the electromechanical devices or 
prosthetic implants. But a unanimously accepted concept 
of  medical products derived from tissue engineering and 
regenerative medicine is yet to develop. Several terms have 
been proposed, for example, “tissue engineered medical 
product” (TEMP) and “tissue engineered product” (TEP), 
and several definitions have been given which cover the 
characteristics of  these medical products.
The term TEMP has been defined in a standard document 
of  the American Society for Testing and Materials (ASTM). 
TEMP is defined as “a medical product that repairs, 
modifies, or regenerates the recipient’s cells, tissues, and 
organs or their structure and function, or both.”[19] In the 
USA, this terminology standard has been included in the 
FDA-recognized consensus standards database. In this 
definition, what comprises TEMPs is not clarified, and 
just in the following sentences is given the explanation as 
“TEMPs derive their therapeutic potential from various 
components used alone or in various combinations. The 
components might be biological products (i.e. cells, organs, 
tissues, derivatives, and processed biologics), biomaterials 
(i.e. substrates and scaffolds), biomolecules, devices, 
and drugs.” This means if  a TEMP is only composed of  
cell, biomaterial scaffold, or chemical alone, it might be 
correspondingly thought as a biological product, medical 
device, or drug, respectively, and is included in the regulatory 
regimes that have been developed for these medical 
products. But in more complex instances, the TEMPs might 
be composed of  any combinations of  drugs, devices, and 
biological products, where such applications fall under the 
category of  combination products.
The regulatory framework for combination products has 
been developed in the FDA during the last decade. A 
combination product is assigned to an agency center or 
alternative organizational component that will have primary 
jurisdiction for its premarket review and regulation. The 
assignment is based on determination of  the primary mode 
of  action (PMOA) of  the combination product.[20] For 
example, if  the PMOA of  a device–biological combination 
product is attributable to the biological product, the 
agency responsible for premarket review of  that biological 
product will have primary jurisdiction for the combination 
product. Apligraf  is a bilayered tissue construct consisting 
of  allogeneic keratinocytes, fibroblasts, and bovine type I 
collagen. At first, Apligraf  had been approved as a medical 
device for the treatment of  venous leg and diabetic foot 
ulcers;[21] but now following the jurisdiction mechanism 
of  the combination product, this product is diverted to a 
biologics license application (BLA) regulatory pathway for 
the treatment of  surgically created gingival and alveolar 
mucosal surface defects in adults.[22]
In the EU, the term TEP is proposed and the definition is: 
“A product that contains or consists of  engineered cells 
or tissues, and is presented as having properties for, or is 
used in or administered to human beings with a view to 
regenerating, repairing, or replacing a human tissue.”[14] The 
definition of  TEP is similar to that of  TEMP recognized 
by the FDA, where the tissue repairing, replacing, or 
regenerating potential of  the product is emphasized, but 
there exist significant differences. The engineered cells are 
considered as indispensable components of  TEPs, and that 
TEPs are classified as advanced therapy medicinal products 
might be attributed to this. When the TEP incorporates, as 
an integral part of  the product, one or more medical devices, 
it is thought as the combined advanced therapy medicinal 
product because where a product contains viable cells or 
tissues, the pharmacological, immunological, or metabolic 
action of  those cells or tissues should be considered as the 
principal mode of  action of  the product.
When medical products derived from tissue engineering and 
regenerative medicine are intended to be used in clinic, their 
components and action modes will be so diversified and the 
attributes of  these medical products might be different. The 
regulatory strategy has to make a difficult balance between 
the possibility for patients to gain rapid access to promising 
products and appropriate guarantees on safety and quality. 
It is, therefore, suggested to opt for a two-stage regulatory 
strategy,[23] with the first level built on the existing and newly 
introduced regulatory provisions and the second technical 
level encompassing all the technical requirements for the 
whole development process, from production, handling, 
storage, and transport to traceability of  the donor. Since 
tissue engineering and regenerative medicine are emerging 
and fast-moving fields, the technological development is not 
fully foreseeable. It is worth noting that the capability of  the 
regulation strategy to adapt in a timely manner to scientific 
progress relies, therefore, on its technical level, which can 
be updated and revised in a flexible and rapid manner.
As living cells, biomaterials, and growth factors might be 
involved in tissue engineering and regenerative medicine, 
the existing provisions in relation to medicinal products 
and medical devices can be applicable. Cells are the key 
element in tissue engineering and regenerative medicine. 
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In the USA, to cope with the challenge of  cellular and 
tissue-based products, the “Tissue Action Plan” was 
initiated in 1998. Until 2005, three rules about human cells, 
tissues, and cellular and tissue-based products had been 
issued: “establishment registration and listing,” “eligibility 
determination for donors,” and “current Good Tissue 
Practice.” These three rules, combined with the existing 
rules for drug, biological product, and medical device, 
have constituted the rounded regulatory regime for medical 
products derived from tissue engineering and regenerative 
medicine. At the technical level, many important guidance 
documents have been also issued timely,[24] for example, 
“guidance of  chemistry, manufacturing, and control (CMC) 
information for human somatic cell therapy investigational 
new drug applications.” In the EU, the integrated regulatory 
framework is on the way. The new regulation No. 
1394/2007 is provided for TEP marketing authorization 
procedure. Some technical guidance documents have been 
issued, for example, “guideline on cell-based medicinal 
products.”[25] But some technical requirements, like Good 
Manufacturing Practice and Good Clinical Practice, have 
not been developed in detail yet.[23]
Current status of regulation and challenge 
in China
In China, if  the application of  tissue engineering and 
regenerative medicine is intended to follow the regulation 
mode of  medical product, there are several provisions 
and guidance that can be referred to. When the product 
is composed of  cell and biomaterial, it is considered as a 
combination product,[26] which might be applied for the 
product classification at first, if  this kind of  combination 
product has not obtained the marketing approval before 
in China. This is also based on a determination of  the 
PMOA of  the combination product to define it as a drug or 
a medical device. At present, there has been only one such 
combination product which has obtained the marketing 
approval in China, the “Activskin” tissue-engineered 
skin composed of  human keratinocytes, fibroblasts, and 
collagen, and approved as a medical device.[27] Following 
the given classification of  medical device, other tissue-
engineered skin products also might apply for marketing 
approval as medical device either, in which guidance 
“Requirements for Tissue Engineered Medical Product 
Research and Registration Application”[28] should be 
referred to. But this guidance is limited; it only covers 
tissue-engineered medical products applying for registration 
as medical device.
In this guidance, the term “tissue engineered medical 
product” is proposed and the definition is provided as 
a medical product that is produced by the principle and 
technique of  tissue engineering, and repairs, modifies, or 
regenerates the structure and function of  tissues and organs. 
It is worth noting that human somatic cell therapy product 
consisting of  cells only is excluded from the scope of  “tissue 
engineered medical product” even if  the human somatic cell 
therapy product is intended to repair, modify, or regenerate 
the structure and function of  tissues and organs. So, if  the 
products derived from tissue engineering and regenerative 
medicine consist of cells only, they will fall in the scope of cell 
therapy products and the document “guidance for human 
somatic cell therapy research and product quality control” 
should be followed to carry out the preclinical studies and 
clinical assessment.[17] The requirements for cell therapy in 
this guidance can also be applicable to the cell component 
of  tissue engineered medical product as the combination 
product. Whether the cells are used alone or combined, the 
biological characteristics of  the cells might be substantially 
altered as a result of  their manipulation, so quality control 
of  processing is mandatory. The principles included in the 
document “guide for processing cells,tissues,and organs” 
can serve as guidance for developing these manufacturing 
procedures of  tissue engineered medical products.[29]
It is recognized that based on existing legislation in relation 
to drugs and medical devices, and newly introduced 
regulatory provisions, a regulatory pathway to premarket 
application of  the products derived from tissue engineering 
and regenerative medicine has been forming in China. 
However, there are only few technical guidelines about 
the manufacture practice, preclinical studies, clinical 
assessment, etc. This means the two-level regulatory strategy 
has not been well developed and the regulatory framework 
of  tissue engineering and regenerative medicine not yet 
finished. Especially when we are aware of  the coexistence 
of  medical product mode and medical technique mode in 
many cases, it is likely that a coherent regulatory framework 
of  tissue engineering and regenerative medicine has not 
been intentionally designed.
If  cells are associated with matrices or scaffolds as the 
integral, they are regarded as combination products with 
the need for premarket approval. The matrices or scaffolds 
which are combined with manipulated cells should meet the 
requirements of medical device regulation. But in the case of  
autologous cells that are combined with biomaterial scaffold 
to repair the structural tissue (skin, bone, cartilage, etc.), it is 
allowed to be carried out as a clinical medical technique,[30] 
and the requirements for matrices and scaffolds are few; just 
the quality standard of  biomaterial and the corresponding 
testing report of  an authorized institute should be provided. 
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More evidences of  conformity of  the medical device 
regulation, including the requirements for manufacture 
practice are absent.
Cell transplantation technique has been approved as a 
third-class medical technique in clinic.[18] Except that 
stem cells are excluded from transplantation, there are 
nearly no other limitations to the usage of  viable cells, 
no matter whether they are autogeneic or allogeneic, 
minimally or substantially manipulated. This means some 
mature/functionally differentiated cell-based treatments 
of  tissue engineering and regenerative medicine can be 
used as medical techniques in clinic; but at the same time, 
they might also fall into the scope of  cell therapy products. 
If  the more desirable regulatory mode is not defined, the 
guarantee on the safety and effectiveness in clinic might be 
impaired or weakened.
Stem cell is the enabling factor in the repair and regeneration 
of  tissues and organs. The usage of  stem cells has not 
been approved as the third-class medical technique in 
clinic since the regulation of  medical technique was 
implemented in 2009. But there were once so many stem 
cell-based treatments offered at a high cost in the absence 
of  rigorous scientific and regulatory requirements.[31] 
There are serious concerns about the safety and efficacy 
of  such treatments. They might lack pharmacological or 
toxicological data from non-clinical studies and generally, 
there are no peer-reviewed publications to demonstrate 
their efficacy. Until recently, the loose regulation on the 
usage of  stem cells in clinic has been changed in China. The 
usage of  stem cells is restricted to the clinical experimental 
research. That means it cannot be advertised and there is no 
charge for the use of  stem cells. The application of  clinical 
experimental research of  stem cells should be subjected to 
a centralized authorization procedure by a top competent 
authority, involving a uniform scientific evaluation of  the 
quality, safety, and efficacy, which should be carried out 
according to the highest possible standards.[32] However, the 
regulation on the stem cell clinical experimental research 
is not applicable to the clinical trial in the development 
process of  stem cell product. For stem cell products, some 
important guidelines on the preclinical study and clinical 
assessment are lacking.
It is obvious that the medical technique mode is adopted in 
so many cases of  clinical application of  tissue engineering 
and regenerative medicine. This is deemed a pragmatic 
regulatory strategy. It tentatively bridges the gap between 
the very rapid progress made in tissue engineering and 
regenerative medicine and their application in the clinic. 
The medical technique mode is not involved with the 
hazards related to the defective products or unforeseen 
mechanisms that can affect thousands of  patients, but 
this situation still requires careful analysis in terms of  the 
risk-benefit weighing. The medical technique mode is 
preferred to be adopted in conditions of  less risk, where 
the cells are minimally manipulated, homologously 
used only, and are not combined with drugs or medical 
devices. In the cases where the cells are subjected to 
substantial manipulation, or are not homologously used, 
or are combined with medical devices, there will be more 
risks which should be taken care of, such as those related 
to transmission of  communicable disease, control of  
processing, and clinical safety and effectiveness concerns. 
Although the quality and safety related rules are required 
to be established in accordance with the relevant criteria 
of  medical product, how these are established depends on 
individual medical institution where the medical technique 
is carried out. There will not be uniform regulation without 
a centralized authorization procedure. On the contrary, 
the regulatory regime of  medical product is characterized 
by the centralized authorization procedure in which the 
scarcity of  expertise in the area can be overcome and a 
uniform scientific evaluation of  the quality, safety, and 
efficacy can be ensured. So, the necessity of  a set of  
flexible regulatory requirements in the clinical application 
of  tissue engineering and regenerative medicine is evident, 
but regarding the choice of  medical technique mode or 
medical product mode, it should be decided on the risk-
based strategy in which more thorough requirements apply 
to objects that are deemed more dangerous.
Conclusion
The above information represents the current regulatory 
situation associated with clinic application of  tissue 
engineering and regenerative medicine, in which it is 
obvious that similar regulatory frameworks are constructed 
in the USA and EU. The risk-based regulatory strategy is 
highlighted which should be the determinant of  the choice 
of  regulatory mode. The mode of  medical technique means 
there are accepted and limited risks imposed on patients. 
To cope with the hazards related to the medical products 
derived from tissue engineering and regenerative medicine 
and promote the commercialization, the two-tier regulatory 
framework composed of  regulatory provisions and 
technique guidelines is suggested to be developed. In China, 
the adoption of  risk-based strategy means there should be 
reconsideration and adjustment of  the present application 
conditions of  medical technique mode. On the other hand, 
the construction of  two-tier regulatory framework which is 
tailored to meet the demands of  development of  medical 
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products of  tissue engineering and regenerative medicine 
still remains a challenge.
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